Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion type Assertion NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_head.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion description "[The TOV-21G, TOV-81D, OV-90, and TOV-112D cell lines were derived from ovarian tumors (TOV) or ascites (OV) from chemotherapy- and radiotherapy-naive patients and were characterized by their mutation spectrum of BRCA2, TGFbeta-RII, KRAS2, TP53, and CDKN2A.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_provenance.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion evidence source_evidence_literature NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_provenance.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion SIO_000772 15258697 NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_provenance.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion wasDerivedFrom befree-20140225 NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_provenance.
- NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_assertion wasGeneratedBy ECO_0000203 NP718514.RAkeUyrF-EyXY-brlowmBlWRLmluJtVx-57k6V7PCYdNk130_provenance.